BioNTech

BioNTech股价逆势上扬：新冠疫苗试验意外终止背后的逻辑

angelina - April 2, 2026

BioNTech Shifts Strategic Focus as COVID Vaccine Trial Concludes

kashif hafeez - April 2, 2026

BioNTech’s Strategic Pivot Gains Traction with Promising Clinical Data

kashif hafeez - April 1, 2026

BioNTech转型阵痛：研发管线扩张难掩市场疑虑

April 1, 2026

BioNTech’s Oncology Ambitions Bolstered by Promising Lung Cancer Trial Data

March 31, 2026

BioNTech肿瘤管线进展引关注：肺癌治疗数据成焦点

angelina - March 29, 2026

BioNTech’s Oncology Ambition: A Pipeline Poised for Multiple Approvals

kashif hafeez - March 28, 2026

哥本哈根会议成试金石：BioNTech肿瘤管线迎来关键考验

March 28, 2026

BioNTech’s Strategic Pivot Gains Momentum with Key Oncology Data

kashif hafeez - March 26, 2026

BioNTech肿瘤管线集中亮相，肺癌大会成关键催化剂

kashif hafeez - March 25, 2026

BioNTech’s Pivotal Year: Clinical Data Holds Key to Oncology Ambitions

kashif hafeez - March 22, 2026

BioNTech 的精准布局：在肿瘤治疗蓝海中开辟新航道

Brett Shapiro - March 22, 2026

生物科技巨头逆势加仓，BioNTech迎来机构抄底潮

Brett Shapiro - March 19, 2026

从mRNA到抗体疗法：BioNTech战略转型背后的机遇与挑战

angelina - March 18, 2026

Leadership Transition at BioNTech: A Strategic Pivot Underway

angelina - March 18, 2026

123...8 Page 2 of 8